Presentations at WORLD Symposium: Vimizim Phase 3 Results and BMN-701 Phase 1/2 Patient Demographics

Presentations at WORLD Symposium: Vimizim Phase 3 Results and BMN-701 Phase
1/2 Patient Demographics

SAN RAFAEL, Calif., Feb. 11, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical
Inc. (Nasdaq:BMRN) announced today that the following presentations will be
featured at the 9^th Annual WORLD Symposium in Orlando, Florida February
13-15, 2013:

On Friday, February 15^th at 9:45 a.m., Dr. Barry Byrne from the University of
Florida, Gainesville will make a presentation titled: POM-001 Phase 1/2 Study
of BMN-701, GILT-tagged Recombinant Human (rh) GAA in Late-Onset Pompe
Disease: Preliminary Report. The presentation will provide background
information on BMN-701, review the design of the Phase 1/2 trial and provide
information on the patient demographics and baseline characteristics of the 22
patients enrolled in the trial. BioMarin remains on track to report efficacy
and safety results for the BMN-701 Phase 1/2 trial by the end of the first
quarter of 2013.

On Friday, February 15^th at 3:15 p.m., Dr. Christian Hendriksz from the
University of Manchester Birmingham Children's Hospital in Lancashire, United
Kingdom will make a presentation titled: A Multinational, Randomized,
Double–Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of
BMN 110 Treatment for Mucopolysaccharidosis IVA (Morquio Syndrome Type A).The
presentation will review efficacy and safety data from the Phase 3 study.

About BioMarin

BioMarin develops and commercializes innovative biopharmaceuticals for serious
diseases and medical conditions. The company's product portfolio comprises
four approved products and multiple clinical and pre-clinical product
candidates. Approved products include Naglazyme® (galsulfase) for
mucopolysaccharidosis VI (MPS VI), a product wholly developed and
commercialized by BioMarin; Aldurazyme® (laronidase) for mucopolysaccharidosis
I (MPS I), a product which BioMarin developed through a 50/50 joint venture
with Genzyme Corporation; Kuvan® (sapropterin dihydrochloride) Tablets, for
phenylketonuria (PKU), developed in partnership with Merck Serono, a division
of Merck KGaA of Darmstadt, Germany; and Firdapse™ (amifampridine), which has
been approved by the European Commission for the treatment of Lambert Eaton
Myasthenic Syndrome (LEMS). Product candidates include BMN-110
(N-acetylgalactosamine 6-sulfatase), formally referred to as GALNS, which
successfully completed Phase III clinical development for the treatment of MPS
IVA, PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is
currently in Phase II clinical development for the treatment of PKU, BMN-701,
a novel fusion protein of insulin-like growth factor 2 and acid alpha
glucosidase (IGF2-GAA), which is currently in Phase I/II clinical development
for the treatment of Pompe disease, BMN-673, a poly ADP-ribose polymerase
(PARP) inhibitor, which is currently in Phase I/II clinical development for
the treatment of genetically-defined cancers, and BMN-111, a modified
C-natriuretic peptide, which is currently in Phase I clinical development for
the treatment of achondroplasia. For additional information, please visit Information on BioMarin's website is not incorporated by
reference into this press release.

The BioMarin Pharmaceutical Inc. logo is available at

Forward-Looking Statement

This press release contains forward-looking statements about the business
prospects of BioMarin Pharmaceutical Inc., including, without limitation,
statements about: expectations related to the Zacharon development programs,
and the development of BioMarin's other programs, including GALNS; and actions
by regulatory authorities. These forward-looking statements are predictions
and involve risks and uncertainties such that actual results may differ
materially from these statements. These risks and uncertainties include, among
others: results and timing of current and planned preclinical studies and
clinical trials; the content and timing of decisions by the U.S. Food and Drug
Administration, the European Commission and other regulatory authorities
concerning each of the described products and product candidates; and those
factors detailed in BioMarin's filings with the Securities and Exchange
Commission, including, without limitation, the factors contained under the
caption "Risk Factors" in BioMarin's 2011 Annual Report on Form 10-K, and the
factors contained in BioMarin's reports on Form 10-Q. Stockholders are urged
not to place undue reliance on forward-looking statements, which speak only as
of the date hereof. BioMarin is under no obligation, and expressly disclaims
any obligation to update or alter any forward-looking statement, whether as a
result of new information, future events or otherwise.

BioMarin^®, Naglazyme^®, Kuvan^® and Firdapse™ are registered trademarks of
BioMarin Pharmaceutical Inc.

Aldurazyme^® is a registered trademark of BioMarin/Genzyme LLC.

CONTACT: Investors:
         Eugenia Shen
         BioMarin Pharmaceutical Inc.
         (415) 506-6570
         Debra Charlesworth
         BioMarin Pharmaceutical Inc.
         (415) 455-7451

BioMarin Pharmaceutical Inc. Logo
Press spacebar to pause and continue. Press esc to stop.